CELEX: 62020TA0584
Language: en
Date: 2021-09-08 00:00:00
Title: Case T-584/20: Judgment of the General Court of 8 September 2021 — Cara Therapeutics v EUIPO — Gebro Holding (KORSUVA) (EU trade mark — Opposition proceedings — Application for the EU word mark KORSUVA — Earlier national word mark AROSUVA — Relative ground for refusal — Likelihood of confusion — Article 8(1)(b) of Regulation (EU) 2017/1001)

25.10.2021   
            
            
               EN
            
            
               Official Journal of the European Union
            
            
               C 431/36
            
         
      Judgment of the General Court of 8 September 2021 — Cara Therapeutics v EUIPO — Gebro Holding (KORSUVA)
      (Case T-584/20) (1)
      
      (EU trade mark - Opposition proceedings - Application for the EU word mark KORSUVA - Earlier national word mark AROSUVA - Relative ground for refusal - Likelihood of confusion - Article 8(1)(b) of Regulation (EU) 2017/1001)
      (2021/C 431/43)
      Language of the case: English
      
         Parties
      
      
         Applicant: Cara Therapeutics, Inc. (Wilmington, Delaware, United States) (represented by: J. Day, Solicitor, and by T. de Haan, lawyer)
      
         Defendant: European Union Intellectual Property Office (represented by: J. Ivanauskas and V. Ruzek, acting as Agents)
      
         Other party to the proceedings before the Board of Appeal of EUIPO, intervener before the General Court: Gebro Holding GmbH (Fieberbrunn, Austria) (represented by: M. Konzett, lawyer)
      
         Re:
      
      Action brought against the decision of the Fourth Board of Appeal of EUIPO of 3 July 2020 (Case R 2450/2019-4), relating to opposition proceedings between Gebro Holding and Cara Therapeutics.
      
         Operative part of the judgment
      
      The Court:
      
                  1.
               
               
                  Dismisses the action;
               
            
                  2.
               
               
                  Orders Cara Therapeutic, Inc. to pay the costs.
               
            
         (1)  OJ C 390, 16.11.2020.